Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignanciesPrithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2016
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerEve T Rodler, Brenda F Kurland, Melissa Griffin, et al.
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomasShivaani Kummar, Jiuping Ji, Robert Morgan, et al.
Cancer Chemotherapy and Pharmacology|September 25, 2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignanciesLeonard J Appleman, Jan H Beumer, Yixing Jiang, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
ATR kinase inhibitors induce mitochondrial fission in CD8 + T cells and impair immune memory in vivoFrank P Vendetti, Carina R Sclafani, Yunqi Zhang, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2016
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumorsShivaani Kummar, Alice Chen, Martin Gutierrez, et al.
The Oncologist|April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)Adel Mandl, Ruizhe Chen, Satya Das, et al.
Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2025
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Larry V Rubinstein, et al.
Pageof 20